Ajanta Pharma's Bonus share in the ratio of 1:2

Nearly 4% down Shares

 Shares of Ajanta Pharma closed nearly 4% lower at ₹1,653 apiece on the BSE

Approval of Bonus equity shares

Board of Ajanta Pharma has approved the issue of equity share in the ratio of 1:2.

Approval of Bonus equity shares

The company said that the bonus shares issue will be out of free reserves of the company as on 31st March, 2022.

Approval of Bonus equity shares

Bonus shares are fully paid additional shares issued by a company to its existing shareholders.

Approval of Bonus equity shares

Ajanta Pharma's revenue from operations for the fourth quarter (Q4FY22) came at ₹870 crore, up 15% as against ₹757 crore in the same quarter last year.

Approval of Bonus equity shares

Its net profit, however, slipped slightly to ₹151 crore from ₹159 crore year-on-year (YoY).

Profile of Ajanta Pharma

Ajanta Pharma is a specialty pharmaceutical company engaged in development, manufacture and marketing of finished dosages in domestic and international markets.

Pharma Stock

The pharma stock is down more than 17% in a year's period whereas it has fallen over 25% in 2022 (YTD) so far.

Visit our blog